{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:45:56Z","timestamp":1792532756225,"version":"4.5.0"},"reference-count":22,"publisher":"Scientific Scholar","content-domain":{"domain":["ijmr.org.in"],"crossmark-restriction":true},"short-container-title":["Indian J Med Res"],"abstract":"\n Background & objectives<\/jats:title>\n Polycystic ovary syndrome (PCOS) is a common endocrinopathy characterised by menstrual irregularities, hirsutism, acne, obesity, infertility, and other features adversely affecting the quality of life of women of childbearing age. Besides lifestyle modifications, limited pharmacological treatments have been used to manage the symptoms of PCOS. This meta-analysis was conducted to evaluate a novel pharmacological approach, sodium glucose cotransporter-2 inhibitors (SGLT2i), in PCOS.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Electronic databases were searched systematically for literature published before November 2024. Randomised controlled trials (RCTs) evaluating SGLT2i alone or in combination in women diagnosed with PCOS, based on the Rotterdam criteria, were included in the meta-analysis. Preclinical studies, and non-randomised trials, were excluded. Quality of studies was assessed using RoB 2.0. Meta-analysis was performed for change in anthropometry, reproductive hormone levels, glycaemic and cardiometabolic indices. Adverse events (AEs) were also compared between the SGLT2i and control groups, using RevMan 5.4.1. Mean difference using the inverse-variance method and 95% confidence interval was used as a measure of effect size of continuous variables, while odds ratio (OR)using the Mantel-Haenszel method (M-H) with 95% confidence interval was calculated to analyse dichotomous variables.\n P<\/jats:italic>\n value less than 0.5 was the cut-off for significance. Trial sequential analysis (TSA) was conducted to test the conventional and required information size (RIS) boundaries. The meta-analysis was registered in PROSPERO (CRD42024608736).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Five RCTs with \u2018low\u2019 risk of bias, including 205 patients with PCOS, receiving SGLT2i (empagliflozin, licogliflozin, dapagliflozin, and canagliflozin alone and in combination with metformin) or control (placebo, metformin, or exenatide) were evaluated in the meta-analysis. SGLT2i significantly reduced total testosterone (mean difference=-0.10 [-0.19, -0.01],\n P<\/jats:italic>\n =0.03), free androgen index (mean difference = -0.61 [-1.16, -0.05],\n P<\/jats:italic>\n =0.03), and homeostasis model assessment-estimated insulin resistance (HOMA-IR) (mean difference = -0.38 [-0.75, -0.02],\n P<\/jats:italic>\n =0.04). Total cholesterol (mean difference=0.13 [0.01, 0.26],\n P<\/jats:italic>\n =0.04) and low-density cholesterol (MD=0.18 [0.06, 0.31],\n P<\/jats:italic>\n =0.003) increased with SGLT2i use. Genitourinary AEs were more common in the SGLT2i group (OR=10.88 [1.33, 89.14],\n P<\/jats:italic>\n = 0.03). On performing TSA, the Z-curve did not cross the RIS boundary of 80 per cent power.\n <\/jats:p>\n <\/jats:sec>\n \n Interpretation & conclusions<\/jats:title>\n The findings of this meta-analysis suggest that SGLT2i improves the hormonal and glycaemic indices in patients with PCOS. It can prove to be a safe alternative in patients not responding to or intolerant of standard pharmacological treatments.<\/jats:p>\n <\/jats:sec>","DOI":"10.25259\/ijmr_497_2025","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T11:18:19Z","timestamp":1762946299000},"page":"313-322","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy & safety of sodium-glucose cotransporter-2 inhibitors in polycystic ovary syndrome: A meta-analysis with trial sequential analysis"],"prefix":"10.25259","volume":"162","author":[{"given":"Marya","family":"Ahsan","sequence":"first","affiliation":[{"name":"Department of Pharmacology, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaz Khurram","family":"Mallick","sequence":"additional","affiliation":[{"name":"Department of Clinical Biochemistry, College of Medicine, King Khalid University, Abha, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"10.25259\/IJMR_497_2025\/ref-1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/GRF.0000000000000563","article-title":"Clinical presentation and diagnosis of polycystic ovarian syndrome","volume":"64","author":"Lentscher","year":"2021","journal-title":"Clin Obstet Gynecol"},{"key":"10.25259\/IJMR_497_2025\/ref-2","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1210\/clinem\/dgad463","article-title":"Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome","volume":"108","author":"Teede","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.25259\/IJMR_497_2025\/ref-3","doi-asserted-by":"publisher","first-page":"e15858","DOI":"10.14814\/phy2.15858","article-title":"SGLT\u20102 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model","volume":"11","author":"Mahmoud","year":"2023","journal-title":"Physiol Rep"},{"key":"10.25259\/IJMR_497_2025\/ref-4","doi-asserted-by":"publisher","first-page":"1457268","DOI":"10.3389\/fendo.2024.1457268","article-title":"Impact of dapagliflozin on metabolic phenotype, hormone levels, and fertility in female mice after prolonged high-fat diet","volume":"15","author":"Chen","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.25259\/IJMR_497_2025\/ref-5","doi-asserted-by":"publisher","first-page":"100335","DOI":"10.1016\/j.jcte.2024.100335","article-title":"SGLT2 inhibitors: Beyond glycemic control","volume":"35","author":"Hasan","year":"2024","journal-title":"J Clin Transl Endocrinol"},{"key":"10.25259\/IJMR_497_2025\/ref-6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s13300-020-00789-y","article-title":"Basic and clinical pharmaco-therapeutics of SGLT2 Inhibitors: a contemporary update","volume":"11","author":"Kalra","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.25259\/IJMR_497_2025\/ref-7","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: Mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.25259\/IJMR_497_2025\/ref-8","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.amjmed.2017.04.009","article-title":"Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: Potential mechanisms","volume":"130","author":"Staels","year":"2017","journal-title":"Am J Med"},{"key":"10.25259\/IJMR_497_2025\/ref-9","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/cen.13968","article-title":"Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomized controlled study","volume":"90","author":"Javed","year":"2019","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.25259\/IJMR_497_2025\/ref-10","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1111\/dom.14495","article-title":"Licogliflozin versus placebo in women with polycystic ovary syndrome: a randomized, double\u2010blind, phase 2 trial","volume":"23","author":"Tan","year":"2021","journal-title":"Diabetes Obesity Metabolism"},{"key":"10.25259\/IJMR_497_2025\/ref-11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/dom.14583","article-title":"Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: a randomized, open\u2010label, noninferiority trial","volume":"24","author":"Cai","year":"2022","journal-title":"Diabetes Obesity Metabolism"},{"key":"10.25259\/IJMR_497_2025\/ref-12","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1210\/clinem\/dgab408","article-title":"Exenatide, dapagliflozin, or phentermine\/topiramate differentially affect metabolic profiles in polycystic ovary syndrome","volume":"106","author":"Elkind-Hirsch","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"10.25259\/IJMR_497_2025\/ref-13","doi-asserted-by":"publisher","first-page":"1003238","DOI":"10.3389\/fendo.2022.1003238","article-title":"Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: a single-center, open-labeled prospective randomized controlled trial","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.25259\/IJMR_497_2025\/ref-14","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.25259\/IJMR_497_2025\/ref-15","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.25259\/IJMR_497_2025\/ref-16","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.25259\/IJMR_497_2025\/ref-19","article-title":"Chapter 6: Choosing effect measures and computing estimates of effect","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024)","author":"Higgins","year":"2024"},{"key":"10.25259\/IJMR_497_2025\/ref-22","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1093\/ejendo\/lvad098","article-title":"The impact of metformin with or without lifestyle modification versus placebo on polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"189","author":"Melin","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"10.25259\/IJMR_497_2025\/ref-23","doi-asserted-by":"publisher","first-page":"108834","DOI":"10.1016\/j.jdiacomp.2024.108834","article-title":"The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials","volume":"38","author":"Austreg\u00e9silo de Athayde De Hollanda Morais","year":"2024","journal-title":"J Diabetes Complications"},{"key":"10.25259\/IJMR_497_2025\/ref-24","doi-asserted-by":"publisher","first-page":"105068","DOI":"10.1016\/j.phrs.2020.105068","article-title":"Effect of sodium-glucose co-transporter 2 inhibitors on lipid profile: a systematic review and meta-analysis of 48 randomized controlled trials","volume":"160","author":"S\u00e1nchez-Garc\u00eda","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.25259\/IJMR_497_2025\/ref-25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3390\/metabo11020087","article-title":"The effects of SGLT2 inhibitors on lipid metabolism","volume":"11","author":"Szekeres","year":"2021","journal-title":"Metabolites"},{"key":"10.25259\/IJMR_497_2025\/ref-26","doi-asserted-by":"publisher","first-page":"830401","DOI":"10.3389\/fendo.2022.830401","article-title":"A meta-analysis of the effect of sodium glucose cotransporter-2 inhibitors on metabolic parameters in patients with polycystic ovary syndrome","volume":"13","author":"Sinha","year":"2022","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["The Indian Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ijmr.org.in\/efficacy-safety-of-sodium-glucose-cotransporter-2-inhibitors-in-polycystic-ovary-syndrome-a-meta-analysis-with-trial-sequential-analysis\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ijmr.org.in\/efficacy-safety-of-sodium-glucose-cotransporter-2-inhibitors-in-polycystic-ovary-syndrome-a-meta-analysis-with-trial-sequential-analysis\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T11:18:20Z","timestamp":1762946300000},"score":1,"resource":{"primary":{"URL":"http:\/\/ijmr.org.in\/efficacy-safety-of-sodium-glucose-cotransporter-2-inhibitors-in-polycystic-ovary-syndrome-a-meta-analysis-with-trial-sequential-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":22,"alternative-id":["10.25259\/IJMR_497_2025"],"URL":"https:\/\/doi.org\/10.25259\/ijmr_497_2025","relation":{},"ISSN":["0971-5916"],"issn-type":[{"value":"0971-5916","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"article-number":"313"}}